Ernexa Therapeutics (ERNA) Return on Sales (2016 - 2025)
Historic Return on Sales for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to 966.32%.
- Ernexa Therapeutics' Return on Sales fell 9116900.0% to 966.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 966.32%, marking a year-over-year decrease of 8949900.0%. This contributed to the annual value of 74.26% for FY2024, which is 1424200.0% up from last year.
- Per Ernexa Therapeutics' latest filing, its Return on Sales stood at 966.32% for Q3 2025, which was down 9116900.0% from 86.41% recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Return on Sales registered a high of 7576.79% during Q3 2022, and its lowest value of 966.32% during Q3 2025.
- Over the past 5 years, Ernexa Therapeutics' median Return on Sales value was 83.39% (recorded in 2025), while the average stood at 527.65%.
- Per our database at Business Quant, Ernexa Therapeutics' Return on Sales skyrocketed by 76679200bps in 2022 and then plummeted by -76864100bps in 2023.
- Ernexa Therapeutics' Return on Sales (Quarter) stood at 91.13% in 2021, then soared by 2026bps to 1755.57% in 2022, then plummeted by -107bps to 125.57% in 2023, then plummeted by -142bps to 304.16% in 2024, then tumbled by -218bps to 966.32% in 2025.
- Its Return on Sales was 966.32% in Q3 2025, compared to 86.41% in Q2 2025 and 83.39% in Q1 2025.